FDA Clears Sequel Automated Insulin Delivery System for Type 2 Diabetes
Regulators in the United States have expanded the clearance for Sequel’s automated insulin delivery platform, the Twiist system, allowing its use among individuals diagnosed with Type 2 diabetes. The device was previously cleared for patients managing Type 1 diabetes.
Expanding Automated Insulin Delivery Options
The regulatory clearance broadens the availability of advanced diabetes technology for a larger patient population. Automated insulin delivery systems are designed to continuously monitor glucose metrics and adjust hormone delivery automatically, reducing the daily management burden for patients.
Key Features of the Twiist System
- Designed to automate insulin administration based on real-time data
- Previously authorised for individuals managing Type 1 diabetes
- Now approved for broader clinical use in Type 2 diabetes populations
Medical device manufacturers continue to develop targeted technologies to assist patients with varying forms of diabetes, though clinical integration and patient training remain essential components of successful disease management.
